Vaxinano is dedicated to developing innovative vaccines targeting veterinary and human infectious diseases including zoonotic diseases, in line with the One Health approach, which highlights the close link between human, animal, and environmental health. It is estimated that around 60% of human infectious diseases originate from animals, emphasizing the importance of addressing these threats at their source.

In today’s global context, increasing interactions between humans and animals driven by urbanization, deforestation, and globalization are leading to greater exposure to emerging infectious diseases. By focusing on pathogens that can cross species barriers, Vaxinano aims to prevent outbreaks before they spread widely. Through advanced vaccine technologies and collaboration with experts in human and veterinary health, the company contributes to reducing pandemic risks and promoting a safer, more sustainable future.